Calbiochem[®]

User Protocol QIA61 Rev. 25 November 2008 RFH Page 1 of 10

TGFα- ELISA Kit Cat. No. QIA61



Note that this user protocol is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions. Full details are available at www.calbiochem.com.

Table of Contents	Page
Intended Use	1
Background	2
Principle of the Assay	3
Materials Provided	3
Materials Required But Not Provided	4
Precautions and Recommendations	4
Sample Preparation	5
Detailed Protocol	6
Evaluation of Results	8
Standard Curve	8
Assay Characteristics	8
Sensitivity	8
Biological Experiments	9
Linearity of Dilution	10
Precision	10
Reagent Stability	11
References	11

Storage

Upon receipt, **standards must be stored at -20°C**. All other components may be stored at -20°C or 4°C (do not refreeze after thawing). Do not expose reagents to excessive light. Allow kit reagents to warm to room temperature before use.

Intended Use

The Calbiochem[®] TGF α ELISA is a non-isotopic immunoassay for the *in vitro* quantitation of human Transforming Growth Factor Alpha (TGF α) in serum, tissue culture media, and other fluids.

Background


Transforming growth factors (TGFs) are potent mitogenic polypeptides. Two classes of TGFs have been identified: TGF α and TGF β . TGF α is synthesized as a 160 amino acid, transmembrane precursor. The precursor undergoes sequential external proteolytic cleavage, releasing TGFα species ranging in molecular weight from 6-25 kDa. Mature TGF α is an acid- and heat-stable 50 amino acid polypeptide of 5.5 kDa . It is secreted by a variety of transformed cells and tumors, and by a number of embryonic cells as well as some normal adult tissues including the brain and skin keratinocytes. Mature TGF α is approximately 30% homologous, at the amino acid level, to epidermal growth factor (EGF). $TGF\alpha$ binds to the EGF receptor, mediates tyrosine phosphorylation of the receptor, and promotes anchorage-independent growth of normal rat fibroblasts in soft agar in the presence of transforming growth factor-beta. Transformation of cells, in vitro, by certain viruses including SV40 and polyoma virus, as well as transformation by the activated ras oncogene can lead to increased secretion of TGF α . TGF α may play a role in tumor formation by an autocrine/paracrine mechanism whereby TGFα promotes and sustains the transformed character of the cells from which it is secreted as well as that of neighboring cells. The biological relevance of TGF α in tumor development is supported by reports that multiple molecular weight forms of TGF α may be found in the urine of cancer patients in amounts which differ from those found in normal urine samples. TGF α may also play a role in normal development including wound healing. The major difficulty impeding the investigation of the normal and pathological roles of $TGF\alpha$ in vivo has been the use of activity-based biological assays that do not distinguish between TGF α and other related molecules (e.g., EGF). The Calbiochem® TGF α ELISA is highly specific and can detect less than 10 pg/ml of human TGF α in a variety of biological fluids and tissue culture media.

Principle of the Assay

The Calbiochem® TGF α ELISA is a "sandwich" enzyme immunoassay which utilizes affinity purified goat polyclonal antibodies specific for mammalian TGF α . Polyclonal TGF α antibodies have been immobilized onto the surface of the plastic wells provided in the kit. The sample to be assayed and biotinylated goat TGF α antibodies, are added to the wells, and allowed to incubate for a period of time. During this time, any TGF α present in the sample binds to both the capture antibody on the plate, and to the reporter antibody (biotinylated) in solution. Unbound material is washed away. The reporter antibody is bound, in turn, by streptavidin-horseradish peroxidase.

The horseradish peroxidase catalyzes the conversion of the chromogenic substrate o-phenylenediamine dihydrochloride from a colorless solution to a light amber solution, the intensity of which is proportional to the amount of $TGF\alpha$ bound to the plate. After stopping further color development, the colored reaction product is measured using a spectrophotometer. Quantitation is achieved by the construction of a standard curve using known concentrations of $TGF\alpha$. By comparing the absorbance obtained from a sample containing an unknown amount of $TGF\alpha$ with that obtained from the standards, the concentration of $TGF\alpha$ in the sample can be determined.

Summary of Procedure



Materials Provided

Standards should be assayed in duplicate. A standard curve must be performed on the same plate and at the same time as the samples. The $TGF\alpha$ ELISA provides sufficient reagents to run two sets of standard curves, and 41 samples (if assayed in duplicate all at once using one standard curve), or 34 samples (if assayed on two separate occasions using two standard curves).

- TGF alpha Polyclonal Antibody Coated Plate: 96 removable wells coated with TGFα polyclonal antibody.
- TGF α Standards: two vials containing lyophilized, synthetic, biologically active TGF α .
 - > Reconstituted standards should be discarded after one use.

- Plate Sealers: Plate sealers are provided to cover the plate during incubations.
- Reporter Antibody: (500 μl) 20X concentrated solution of biotinylated goat TGFα antibody.
- **Peroxidase Conjugate:** (200 μl) 100X concentrated solution of streptavidin conjugated to horseradish peroxidase.
- Peroxidase Substrate: (5 tablets) O-Phenylenediamine (OPD) and (20 ml) Substrate Diluent.
- Stop Solution: (20 ml) 2.5 sulfuric acid.
- Rinse Buffer: (30 ml) 10X concentrated buffer containing bovine serum albumin, a surfactant and 0.1% 2-chloroacetamide.
- Antigen Extraction Agent (AEA): Use as directed in sample preparation section for the extraction of $TGF\alpha$ from cell preparations
- Assay Buffer: (30 ml) Buffer containing bovine serum albumin, a surfactant, protein stabilizers and 0.1% 2-chloroacetamide.

NOTE: The amount of Assay Buffer provided is sufficient when used as directed. Use only as much Assay Buffer as needed to ensure delivery of 100 µl of sample to each well. If a large excess of diluent sample is prepared (e.g., 1 ml rather than 0.22 ml needed for each sample, in duplicate) Assay Buffer may become limiting.

Wash Buffer: (100 ml) 20X concentrated buffer and surfactant.

Materials Required but not Provided

- 2-20 μl, 20-200 μl and 200-1000 μl precision pipetters with disposable tips.
- Wash bottle or multichannel dispenser for washing.
- Microcentrifuge tubes or other appropriate containers for mixing low volumes.
- 1 liter graduated cylinder.
- Deionized H₂O.
- Plastic wrap.
- · Adhesive tape.
- Spectrophotometer capable of measuring absorbance in 96-well plates at a wavelength of 490 nm. Use of a 630 nm reference beam is suggested.
- Disposable paper towels.
- 2 µm syringe filter and syringe.

Precautions and Recommendations

- Store **standards at -20°C**. All other components may be stored at -20°C or 4°C (do not refreeze after thawing). Do not expose reagents to excessive light. Warm kit reagents to room temperature before use (let sit at room temperature approximately 30 min before use.)
- Use only the wells provided with the kit.
- Do not mix reagents from different kits.
- The buffers and reagents used in this kit contain 2-chloroacetamide. Care should be taken to prevent direct contact with these products.
- Do not mouth pipette or ingest any of the reagents.
- Do not smoke, eat, or drink when performing the assay or in areas where samples or reagents are handled.
- Human samples may be contaminated with infectious agents. Do not ingest, expose to open wounds, or breathe aerosols. Dispose of samples properly.
- Do not handle the substrate tablets with fingers or permit contact with skin, metal or oxidizing agents. Dispose of OPD (*o*-phenylenediamine) containing solutions in compliance with local regulations.
- Wear disposable gloves and eye protection when handling Stop Solution (2.5N sulfuric acid).

Sample Preparation

Cell Lysate Protocol. Numerous extraction protocols can be used. The following protocol has been shown to work with a number of cell lines. It is provided as an example of a suitable extraction procedure, but should not be construed as necessarily being the method of choice. Users may wish to experiment with extraction procedures that work best in their hands.

- 1. For suspension cells, pellet by centrifugation, remove supernatant, resuspend with PBS and pellet by centrifugation. For attached cells, remove supernatant from cells (you may save the supernatant for testing in the ELISA). Wash cells once with PBS, harvest cells by scraping and gentle centrifugation.
- 2. Aspirate PBS leaving an intact cell pellet (at this point the cell pellet can be frozen at –80°C and lysed at a later date). We recommend for every 5 x 10⁶ cells, resuspend the pellet in 1 ml of Resuspension Buffer (50 mM Tris containing 5 mM EDTA, 0.2 mM PMSF, 1 ug/ml pepstatin, and 0.5 ug/ml of leupeptin adjusted to pH 7.4.
- 3. Add 20 µl of Antigen Extraction Agent (AEA provided) for every 100 µl of cell suspension.
- 4. Incubate 30 min on ice with occasional vortexing.
- Transfer extracts to microcentrifuge tubes and centrifuge for 5 min at 500 x g at 4°C.
- 6. Aliquot cleared lysate to clean microcentrifuge tubes. The sample should be aliquotted to avoid multiple freeze/thaws. These samples are now ready for analysis according to the instructions provided in the Detailed Protocol. Samples may be stored at –20°C for future testing in the TGFα ELISA.
- 7. Samples found to contain greater than 1000 pg/ml TGF α (i.e., outside the range of the standard curve) must be diluted with Assay Buffer (provided), so that the TGF α concentration falls within the range spanned by the standard curve, and assayed again.
- 8. Appropriate negative controls should be included. For example, if TGFα is being measured in cell conditioned medium, a sample of the same medium which has not been exposed to cells should also be assayed.
- 9. Appropriate negative controls should be included. For example, if $TGF\alpha$ is being measured in cell conditioned medium, a sample of the same medium which has not been exposed to cells should also be assayed.

Detailed Protocol

The TGF α ELISA is provided with removable strips of wells so the assay can be carried out on separate occasions. Since conditions may vary, a standard curve must be determined each time the assay is performed. Both standards and samples should be assayed in duplicate. Disposable pipette tips and reagent troughs should be used for all transfers to avoid cross contamination of reagents or samples.

- 1. Remove the appropriate number of wells from the foil pouch. Return any unused wells to the foil pouch containing the desiccant pack. SEAL TIGHTLY and store at 4°C. Let all other kit components sit at room temperature until used. Best results will be obtained using reagents at room temperature.
- 2. Prepare a working solution (1X) of Rinse Buffer by adding 30 ml of 10X concentrated solution to 270 ml of deionized water. Mix well.
- 3. Prepare a working solution (1X) of Wash Buffer by adding 50 ml of the 20X concentrated solution to 950 ml of deionized water. Mix well.
- 4. Reconstitute Lyophilized Standard (refer to vial label for lot specific reconstitution volume of dH₂O and/or Assay Buffer) to yield a stock solution of 1000 pg/ml. Let the reconstituted standard sit for 15 min, with occasional swirling. Avoid excessive agitation of the standard. Serial dilutions of the standard should be made with Assay Buffer. To make serial dilutions of the standard, obtain 6 tubes and label them, 1000, 500, 250, 125, 62.5, 0 pg/ml. Add 250 μl of Assay Buffer into each tube, except the 1000 pg/ml tube (first tube) which gets "undiluted" standard. Remove 500 μl from the undiluted, reconstituted standard vial (1000 pg/ml) and add it to the first tube. Remove 250 μl from the first tube (1000 pg/ml) and add it to the second tube (500 pg/ml) and mix gently. Repeat this procedure until you reach the fifth tube (62.5 pg/ml). The last tube (0 pg/ml) should contain only 250 μl of Assay Buffer.

- 5. Dilute Reporter Antibody 1:20 in Assay Buffer to provide 55 μl of 1X solution for each of the sample and standard wells. (For example: add 60 μl to 1,140 μl of Assay Buffer to make 1.2 ml of working solution, sufficient for 20-21 wells).
- 6. Add 50 µl of diluted Reporter Antibody to appropriate wells, in DUPLICATE.
- 7. Add 50 µl of standards/samples to appropriate wells, in duplicate, on top of reporter antibody.
- 8. Cover plate with a plate sealer and incubate at room temperature for 3 h.
- 9. Dilute a sufficient amount of the Peroxidase Conjugate 1:100 in Assay Buffer to provide 100 μl of 1X solution for each of the sample and standard wells. (For example: add 11 μl to 1,089 μl of Assay Buffer to make 1.1 ml of working solution, sufficient for 10 wells). Filter with a 0.2 μm syringe filter prior to use.
- 10. Wash wells 3 times with 1X Wash Buffer making sure each well is filled completely.
- 11. Wash wells one time using 200 µl of 1X Rinse Buffer per well. Do not let the Rinse Buffer incubate on the plate for more than five min. Empty the contents of the wells by inverting the plate over a sink then tapping dry on paper towels.
- 12. Add 100 µl of the 1X Peroxidase Conjugate into each well. Cover with plastic wrap and incubate 30 min at room temperature.
- 13. Prepare sufficient Substrate Solution to provide 100 μl for each well. Substrate Solution is prepared by dissolving one (1) OPD tablet per 4 ml of Substrate Diluent and mixing gently. Once prepared, substrate solution should be used within 30 min. AVOID EXPOSURE TO LIGHT.
 - **WARNING:** Do not handle substrate tablets with fingers or permit contact with skin, metal or oxidizing agents. If contacted, flush with water. Solutions should be disposed of in compliance with local regulations.
- 14. Wash wells 3 times with 1X Wash Buffer making sure each well is filled completely.
- 15. Wash wells one time using 200 µl of 1X Rinse Buffer per well. Do not let the Rinse Buffer incubate on the plate for more than five min. Empty the contents of the wells by inverting the plate over a sink then tapping dry on paper towels.
- 16. Add 100 µl of Substrate Solution to each well and incubate IN THE DARK at room temperature for 30 min.
- 17. Add 100 µl of Stop Solution to each well in the same order as the previously added Substrate Solution.
- 18. Measure absorbance in each well using a spectrophotometric plate reader at a wavelength of 490 nm. Wells must be read within 30 min of adding the Stop Solution.

Evaluation of Results

- 1. Average the duplicate absorbance values for each standard, including the zero, and all sample values.
- 2. On graph paper, plot the mean absorbance values for each of the standards on the Y axis, versus the concentration of each standard (pg/ml) on the X axis.
- 3. Determine the concentration of unknowns by interpolation from the standard curve. There are a variety of plate reader software packages available (Softmax, Molecular Devices Corporation, Menlo Park, CA; KinetiCalc, BioTek Instruments, Inc. Winooski, VT) for analysis of plate data, which simplifies this process.
- 4. For samples which have been diluted, the TGF α concentration must be multiplied by the dilution factor (ie., if the sample was diluted five-fold, then the TGF α value obtained from the standard curve must be multiplied by five).




Figure 1. Standard Curve. The mean signal of each standard run in replicates of three in eight assays using two different lots of plates and two different lots of detector antibody.

Assay Characteristics

A. Sensitivity

Studies have demonstrated that TGF α ELISA can distinguish 2.1 pg/ml from zero with a 95% confidence, therefor the ELISA can easily distinguish 6 pg/ml from zero.




Figure 2. Sensitivity. The lower limit of detection (LLD), commonly used to define sensitivity, was measured by assaying four replicates of zero eight times using two different lots of plates and two different lots of detector antibody. The grand mean signal and pooled standard deviation of zero was calculated. The grand mean of each standard (run in replicates of three in the eight assays) was used for the standard curve (Figure 3), and the response, mean signal of zero plus two standard deviations. read in dose from the standard curve is the LLD; that is, the smallest dose that is not zero with 95% confidence.

B. Specificity




Figure 3. Levels of $TGF\alpha$ in cell culture supernatants, cellular lysates and recombinant protein detected by the ELISA after immunoaffinity extraction of $TGF\alpha$ by an antibody that is not used in the ELISA.

The TGF α ELISA detects soluble and intracellular TGF α . Specificity was demonstrated by immunoaffinity extraction (inhibition of assay signal) of TGF α positive samples by a specific TGF α antibody. The TGF α antibody, which is not a component of the ELISA, extracted almost all TGF α (almost the entire signal was lost), while the control antibody (non-TGF α antibody) did not affect the signal of the TGF α positive samples (see Figure 2). The non-ELISA TGF α antibody extracts the same portion of the TGF α activity detected by this immunoassay from the biological samples as it did from a recombinant TGF α sample demonstrating that the assay is specificity for the soluble and intracellular TGF α (Figure 2).

No measurable cross-reactivity was observed when human Epidermal Growth Factor (hEGF) and amphiregulin were assayed at a concentration greater of 1000 pg/ml.




Figure 4. Phorbol ester and Concanavalin A induced upregulation of $TGF\alpha$ in MDA MB 231 cells. $TGF\alpha$ is synthesized and transported to the cell surface as a membrane-anchored precursor (pro $TGF\alpha$) that is converted to the soluble form by proteolytic cleavage. Pro $TGF\alpha$ cleavage is activated in response to tumor-promoting phorbol ester. Concanavalin A is a mitogen known to upregulate cytokine production in numerous cell lines.




Figure 5. Parallelism: The study tested dilution-recovery of three positive supernatant and three lyste samples. The dilutions were run in the $\mathsf{TGF}\alpha$ ELISA and the "found" doses were plotted against the "expected" doses to determine linearity of dilution. The slope is close to one and the intercept is not significantly different from zero. These studies are consistent with the absence of cross-reacting and matrix effects such as pH, salts, and endogenous binders that interfere with the reagents used in the assay.




Figure 6. Precision. The pooled coefficients of variation (according to the formula of Henry et. al., 1974) and between assay coefficients of variation are plotted against PCNA levels. The pooled data were collected from samples run eight times using two different lots of plates and two different lots of detector antibody in replicates of three.

Recovery

Human TGF α (900 pg/ml) was added to each of five (5) undiluted normal human sera (NHS) and five (5) undiluted normal human plasma (NHP). The spiked samples were analyzed neat (undiluted) and diluted 1:2, 1:4 and 1:8 with Assay Buffer. Results are expressed as a percent of the expected value +/- one standard deviation.

% of Expected Value				
Sample	Neat	Diluted 1:2	Diluted 1:4	Diluted 1:8
NHP	47+/-18	72+/-20	62+/-19	72+/-17
NHS	47+/-20	54+/-39	38+/-28	32+/-24

Reagent Stability

All of the reagents included with the $TGF\alpha$ ELISA have been tested for stability. Assay Buffer should not be used if cloudiness or solid matter is present. Coated plates should be stored at 4°C in the original foil bag containing a desiccant pack.

References

Ellis, D.L., et al. 1990. J. Invest. Dermatol. 95, 27.

Katoh, M., et al. 1990. Biochem. Biophys. Res. Commun. 167, 1065.

Derynck, R., 1988. Cell 54, 593.

Coffey, R.J., et al. 1987. Nature 328, 817.

Yeh, Y.C., et al. 1987. Cancer Res. 47, 896.

Derynck, R., 1986. J. Cell Biochem. 32, 203.

Samsoondar, J., et al. 1986. J. Biol. Chem. 261, 14408.

Lee, D.C., et al. 1985. Molec. Cell. Biol. 5, 3644.

Todaro, G.J., et al. 1985. *In Genes and Protein in Oncogenesis*, Vogel, H., Weinstein, I.B. (Eds.) New York, Raven Press pp. 165.

Anzano, M.A., et al. 1983. Proc. Natl. Acad. Sci. USA 80, 6264.

Marquardt, H., et al. 1983. Proc. Natl. Acad. Sci. USA 80, 4684.

Reynolds, F.H., Jr., et al. 1983. Nature 292, 259.

Trademarks

Calbiochem® is a registered trademark of EMD Chemicals, Inc.

Prices and availability are subject to change. ©Copyright 2008 EMD Chemicals, Inc., an affiliate of Merck KGaA, Darmstadt, Germany. All rights reserved. Each product is sold with a limited warranty which is provided with each purchase. Each product is intended to be used for research purposes only. It is not to be used for drug or diagnostic purposes nor is it intended for human use. EMD Biosciences products may not be resold, modified for resale, or used to manufacture commercial products without written approval of EMD Chemicals.